The UNC Breast Cancer SPORE Administrative Core has supported the infrastructure, planning, and evaluation of the UNC Breast SPORE since 1992. The Administrative Core and its leaders Earp, Perou, and Carey are responsible for the institutional long-range plans and resource commitments of the Cancer Center?s largest translational portfolio. The functions of the Administrative Core include organizing weekly leadership meetings, monthly SPORE faculty scientific meeting, quarterly Executive Committee and Advocate meetings and the yearly External Advisory Board. The Core collates formal reports to evaluate the progress of all SPORE elements, projects, pilots and career development and mentorship. The Core facilitates interactions with the NCI SPORE program and other NCI SPOREs, as well as multiple breast cancer research collaborations both nationally and internationally. The Core manages the Career Enhancement Program, including conducting external and internal searches for talented potential SPORE investigators; and the Developmental Research Program, including organizing the pilot project competition and facilitating funding and evaluation of DRP projects. The Core follows the accrual to clinical trials and the data on the breast cancer care population including minority accrual. The Administrative Core manages the finances of the SPORE including the substantial institutional commitment to projects, infrastructure and recruitment allocated to leadership, approaching $8M over the last five years as well as the $7-8M commitment for the proposed 5-year renewal. The Core implements the results of evaluations. Through these activities, the UNC Breast SPORE Administrative Core supports an exceptional team of breast cancer translational researchers as they explore and address minority disparities research, genomic analysis, molecular subtyping and therapeutic resistance, while advancing new technology and developing junior faculty into translational research leaders.

Public Health Relevance

The Administration Core supports the four projects and core resources that will continue to explore and address minority disparities research, inflammatory signaling, molecular subtyping and therapeutic resistance, while advancing new technology and developing junior faculty into translational research leaders.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-26
Application #
10011761
Study Section
Special Emphasis Panel (ZCA1)
Project Start
1997-08-05
Project End
2023-08-31
Budget Start
2020-09-01
Budget End
2021-08-31
Support Year
26
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Lei, Jonathan T; Shao, Jieya; Zhang, Jin et al. (2018) Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep 24:1434-1444.e7
Troester, Melissa A; Sun, Xuezheng; Allott, Emma H et al. (2018) Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst 110:
Williams, Michelle M; Lee, Linus; Werfel, Thomas et al. (2018) Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. Cell Death Dis 9:21
Allott, Emma H; Geradts, Joseph; Cohen, Stephanie M et al. (2018) Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Res 20:12
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820

Showing the most recent 10 out of 598 publications